Author: Hitchings, M.; Ranzani, O. T.; Torres, M. S. S.; de Oliveira, S. B.; Almiron, M.; Said, R.; Borg, R.; Schulz, W. L.; de Oliveira, R. D.; da Silva, P. V.; de Castro, D. B.; Sampaio, V. d. S.; de Albuquerque, B. C.; Ramos, T. C. A.; Fraxe, S. H. H.; da Costa, C. F.; Naveca, F. G.; Siqueira, A. M.; de Araujo, W. N.; Andrews, J. R.; Cummings, D. A. T.; Ko, A. I.; Croda, J.
Title: Effectiveness of CoronaVac in the setting of high SARS-CoV-2 P.1 variant transmission in Brazil: A test-negative case-control study Cord-id: b3m11ppy Document date: 2021_4_7
ID: b3m11ppy
Snippet: Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant P.1 emerged in the city of Manaus in late 2020 during a large resurgence of coronavirus disease (COVID-19), and has spread throughout Brazil. The effectiveness of vaccines in settings with widespread P.1 transmission has not been reported. Methods We performed a matched test-negative case-control study to estimate the effectiveness of an inactivated vaccine, CoronaVac, in healthcare workers (HCWs) in Manaus, where P.
Document: Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant P.1 emerged in the city of Manaus in late 2020 during a large resurgence of coronavirus disease (COVID-19), and has spread throughout Brazil. The effectiveness of vaccines in settings with widespread P.1 transmission has not been reported. Methods We performed a matched test-negative case-control study to estimate the effectiveness of an inactivated vaccine, CoronaVac, in healthcare workers (HCWs) in Manaus, where P.1 accounted for 75% of genotyped SARS-CoV-2 samples at the peak of its epidemic. Information from electronic surveillance databases was used to select cases of RT-PCR-confirmed SARS-CoV-2 infection and matched test-negative controls from 19 January, 2021 to 25 March, 2021. We used conditional logistic regression to estimate the effectiveness in reducing the odds of primary and secondary outcomes of, respectively, symptomatic and any SARS-CoV-2 infection. Findings Among 53,176 HCWs, 46,884 (88%) received at least one dose of CoronaVac and 2,656 (5%) underwent RT-PCR testing from 19 January, 2021 to 25 March, 2021. Of 2,797 RT-PCR tests, 776 (28%) were positive. 393 and 135 case-control pairs with and without, respectively, symptomatic illness were selected for the matched analyses. Vaccination with at least one dose was associated with a 0.50-fold reduction (adjusted vaccine effectiveness, 49.6%; 95% CI, 11.3 - 71.4) in the odds of symptomatic SARS-CoV-2 infection during the period 14 days or more after receiving the first dose. Estimated vaccine effectiveness of at least one dose against any SARS-CoV-2 infection was 35.1% (95% CI, -6.6 - 60.5) in the same time period. Interpretation Administration of at least one dose of CoronaVac showed effectiveness against symptomatic SARS-CoV-2 infection in the setting of epidemic P.1 transmission, underscoring the need to increase vaccination efforts in response to the spread of this variant in Brazil and globally. Funding Pan American Health Organization; Fundacao Oswaldo Cruz (Fiocruz); Municipal Health Secretary of Manaus
Search related documents:
Co phrase search for related documents- absence presence and acute respiratory virus: 1, 2, 3, 4, 5
- absence presence and acute respiratory virus coronavirus: 1, 2, 3, 4
- absence presence and adjusted model: 1, 2
- absence presence and administration dose: 1, 2
- absence presence define and acute respiratory virus: 1
- absence presence define and acute respiratory virus coronavirus: 1
- acute respiratory illness and additional analysis: 1
- acute respiratory illness and additional case: 1, 2
- acute respiratory illness and additional vaccine: 1, 2, 3
- acute respiratory illness and adjusted model: 1
- acute respiratory illness and adjusted ve: 1, 2
- acute respiratory virus and additional vaccine: 1, 2
- acute respiratory virus and adjusted model: 1, 2, 3
- acute respiratory virus and administration dose: 1
- acute respiratory virus coronavirus and additional vaccine: 1
- acute respiratory virus coronavirus and adjusted model: 1, 2
- additional analysis and administration dose: 1
- additional vaccine and administration dose: 1, 2, 3
Co phrase search for related documents, hyperlinks ordered by date